ICPT - Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

• Intercept Pharmaceuticals ( NASDAQ: ICPT ) Ocaliva (obeticholic acid) demonstrated a transplant-free survival benefit in patients with primary biliary cholangitis based on clinical trial and real-world data compared to those who didn't receive the treatment.
• Patients on Ocaliva had ~70% lower relative risk of death or liver transplant than control patients at any point during the six-year follow-up.
• The primary outcome -- time to first occurrence of liver failure or death -- favored Ocaliva in the phrase 3 POISE study compared to patients from real-world databases.
• Results were published in the journal Gastroenterology .
• Seeking Alpha's Quant Rating views Intercept ( ICPT ) as a buy with strong marks for momentum and profitability .

For further details see: